1. Home
  2. PHAR vs NMCO Comparison

PHAR vs NMCO Comparison

Compare PHAR & NMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • NMCO
  • Stock Information
  • Founded
  • PHAR 1988
  • NMCO 2019
  • Country
  • PHAR Netherlands
  • NMCO United States
  • Employees
  • PHAR N/A
  • NMCO N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • NMCO Finance/Investors Services
  • Sector
  • PHAR Health Care
  • NMCO Finance
  • Exchange
  • PHAR Nasdaq
  • NMCO Nasdaq
  • Market Cap
  • PHAR 627.5M
  • NMCO 611.9M
  • IPO Year
  • PHAR N/A
  • NMCO N/A
  • Fundamental
  • Price
  • PHAR $9.53
  • NMCO $10.75
  • Analyst Decision
  • PHAR Strong Buy
  • NMCO
  • Analyst Count
  • PHAR 3
  • NMCO 0
  • Target Price
  • PHAR $27.00
  • NMCO N/A
  • AVG Volume (30 Days)
  • PHAR 5.5K
  • NMCO 207.6K
  • Earning Date
  • PHAR 03-13-2025
  • NMCO 01-01-0001
  • Dividend Yield
  • PHAR N/A
  • NMCO 5.43%
  • EPS Growth
  • PHAR N/A
  • NMCO N/A
  • EPS
  • PHAR N/A
  • NMCO N/A
  • Revenue
  • PHAR $285,745,000.00
  • NMCO N/A
  • Revenue This Year
  • PHAR $20.08
  • NMCO N/A
  • Revenue Next Year
  • PHAR $9.22
  • NMCO N/A
  • P/E Ratio
  • PHAR N/A
  • NMCO N/A
  • Revenue Growth
  • PHAR 30.64
  • NMCO N/A
  • 52 Week Low
  • PHAR $6.65
  • NMCO $8.52
  • 52 Week High
  • PHAR $13.20
  • NMCO $11.64
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 51.32
  • NMCO 48.47
  • Support Level
  • PHAR $9.37
  • NMCO $10.60
  • Resistance Level
  • PHAR $10.15
  • NMCO $10.82
  • Average True Range (ATR)
  • PHAR 0.52
  • NMCO 0.12
  • MACD
  • PHAR -0.12
  • NMCO 0.03
  • Stochastic Oscillator
  • PHAR 19.95
  • NMCO 81.08

About PHAR Pharming Group N.V.

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

About NMCO Nuveen Municipal Credit Opportunities Fund

Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.

Share on Social Networks: